- Home
- NRXP vs BRNS Comparison
NRXP vs BRNS Comparison
Compare NRXP & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXP
- BRNS
- Stock Information
- Founded
- NRXP 2015
- BRNS 2016
- Country
- NRXP United States
- BRNS United Kingdom
- Employees
- NRXP N/A
- BRNS N/A
- Industry
- NRXP Biotechnology: Pharmaceutical Preparations
- BRNS Biotechnology: Pharmaceutical Preparations
- Sector
- NRXP Health Care
- BRNS Health Care
- Exchange
- NRXP Nasdaq
- BRNS Nasdaq
- Market Cap
- NRXP 58.5M
- BRNS 58.0M
- IPO Year
- NRXP N/A
- BRNS 2021
- Fundamental
- Price
- NRXP $3.58
- BRNS $1.51
- Analyst Decision
- NRXP Strong Buy
- BRNS Strong Buy
- Analyst Count
- NRXP 5
- BRNS 1
- Target Price
- NRXP $31.40
- BRNS $3.00
- AVG Volume (30 Days)
- NRXP 416.8K
- BRNS 254.2K
- Earning Date
- NRXP 11-13-2025
- BRNS 11-05-2025
- Dividend Yield
- NRXP N/A
- BRNS N/A
- EPS Growth
- NRXP N/A
- BRNS N/A
- EPS
- NRXP N/A
- BRNS N/A
- Revenue
- NRXP N/A
- BRNS $14,969,000.00
- Revenue This Year
- NRXP N/A
- BRNS N/A
- Revenue Next Year
- NRXP $395.09
- BRNS N/A
- P/E Ratio
- NRXP N/A
- BRNS N/A
- Revenue Growth
- NRXP N/A
- BRNS 1766.46
- 52 Week Low
- NRXP $1.10
- BRNS $0.64
- 52 Week High
- NRXP $6.01
- BRNS $2.92
- Technical
- Relative Strength Index (RSI)
- NRXP 67.97
- BRNS 63.56
- Support Level
- NRXP $3.19
- BRNS $1.36
- Resistance Level
- NRXP $3.84
- BRNS $1.83
- Average True Range (ATR)
- NRXP 0.22
- BRNS 0.17
- MACD
- NRXP 0.05
- BRNS 0.05
- Stochastic Oscillator
- NRXP 70.87
- BRNS 68.35
About NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. It has announced the commercialization of ZYESAMI (Aviptadil), an application for COVID-related respiratory failure. The company is also developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About BRNS Barinthus Biotherapeutics plc
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.